Hypertension & Diabetic Kidney
Hypertension, diabetic nephropathy, SGLT2-inhibitor trials, and RAS-blockade evidence relevant to kidney disease, curated by ASNRT.
Browse all news
Explore the full ASNRT newsroom for society announcements, KDIGO guideline updates, AJNT issue releases, and notable developments across the breadth of nephrology.
Latest in this topic
The most recent evidence summaries curated by ASNRT on this topic:
Adding Finerenone to SGLT2 Inhibitors and Long-Term Kidney Outcomes in Diabetic Kidney Disease · SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes · Mechanisms of diabetic kidney disease and established and emerging treatments. · Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of SGLT2 Inhibitors in Patients Hospitalized for Heart Failure · Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors-A Systematic Review. · SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application · Exploring Platelet Indices as Predictors of Nephropathy Severity in Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Analysis. · Novel Insights into Diabetic Kidney Disease. · Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis · Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials · SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. · Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT. · Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. · Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk. · Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials · Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE)